Containing AMR contribution from pharmaceutical effluent involving multi-stakeholders: Dr Anita Kotwani

  10 November 2020

From the environmental sector and specifically from the industry sector, the pharmaceutical industry manufacturing antibiotics play an important role in the development of AMR. The pharmaceutical sector is growing fast and is expected to be worth USD1.57 trillion by 2023. There is a huge increase in the use and manufacturing of antibiotics in the last decade or so. With the rise in antibiotics manufacturing, understandably there is a rise in pharmaceutical effluent generated by the industry. The effluents generated from antibiotic manufacturing units, both active pharmaceutical ingredient (API) and finished pharmaceutical product (FPP) contain antibiotic residues, though higher amounts of antibiotics are expected in the effluent of API manufacturing units. 

Further reading: ET Health World
Author(s): Anita Kotwani,
Clean Environment  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!